ADIL Logo

Adial Pharmaceuticals, Inc. (ADIL) 

NASDAQ
Market Cap
$6.41M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
348 of 790
Rank in Industry
213 of 440

Largest Insider Buys in Sector

ADIL Stock Price History Chart

ADIL Stock Performance

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

Insider Activity of Adial Pharmaceuticals, Inc.

Over the last 12 months, insiders at Adial Pharmaceuticals, Inc. have bought $1,918 and sold $0 worth of Adial Pharmaceuticals, Inc. stock.

On average, over the past 5 years, insiders at Adial Pharmaceuticals, Inc. have bought $70,703 and sold $474,250 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Schuyler Kevin (director) — $3,836.

The last purchase of 700 shares for transaction amount of $1,918 was made by Schuyler Kevin (director) on 2023‑09‑29.

List of Insider Buy and Sell Transactions, Adial Pharmaceuticals, Inc.

2023-09-29PurchaseSchuyler Kevindirector
700
0.0566%
$2.74$1,918-45.86%
2021-12-30PurchaseNewman James W. Jr.director
25,000
0.1356%
$2.69$67,300-53.00%
2021-11-30PurchaseStilley William B. IIIChief Executive Officer
10,600
0.0565%
$2.75$29,179-51.80%
2021-11-29PurchaseStilley William B. IIIChief Executive Officer
10,000
0.0544%
$2.59$25,892-47.27%
2021-11-26PurchaseNewman James W. Jr.director
10,000
0.0538%
$2.85$28,500-52.28%
2021-04-06SaleJohnson Bankole A.Chief Medical Officer
150,000
0.8494%
$2.50$375,000+4.38%
2020-08-20SaleJohnson Bankole A.Chief Medical Officer
350,000
2.0553%
$1.21$423,500+47.02%
2020-03-27PurchaseNewman James W. Jr.director
19,644
0.1848%
$1.36$26,769+23.91%
2020-03-26PurchaseStilley William B. IIIChief Executive Officer
12,652
0.1363%
$1.47$18,598+31.54%
2020-03-25PurchaseStilley William B. IIIChief Executive Officer
12,348
0.1072%
$1.13$13,953+37.90%
2019-12-12SaleJohnson Bankole A.Chief Medical Officer
150,000
0.8506%
$1.00$150,000-7.45%
2019-03-29PurchaseJohnson Bankole A.Chief Medical Officer
33,100
0.4057%
$3.47$114,801-50.44%
2019-03-28PurchaseJohnson Bankole A.Chief Medical Officer
40,000
0.4706%
$3.15$125,808-47.53%
2018-07-31PurchaseStilley William B. IIIChief Executive Officer
80,000
1.8029%
$5.00$400,000-28.75%
2018-07-31PurchaseSchuyler Kevindirector
180,000
2.0282%
$2.50$450,000-28.75%
2018-07-31PurchaseNewman James W. Jr.director
20,000
0.4507%
$5.00$100,000-28.75%
2018-07-31PurchaseGilliland Robertson H.director
14,000
0.3155%
$5.00$70,000-28.75%
2018-07-31PurchaseGoodman Tonydirector
14,000
0.3549%
$5.63$78,750-28.75%
2018-07-31PurchaseJohnson Bankole A.
1,400
0.0316%
$5.00$7,000-28.75%

Insider Historical Profitability

<0.0001%
Schuyler Kevindirector
700
0.0109%
$1.0020<0.0001%
Stilley William B. IIIChief Executive Officer
937646
14.643%
$1.0050<0.0001%
Johnson Bankole A.Chief Medical Officer
548336
8.5632%
$1.0033<0.0001%
Gilliland Robertson H.director
109424
1.7088%
$1.0010<0.0001%
Newman James W. Jr.director
50221
0.7843%
$1.0040<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders